Management of residual disease after chemotherapy in germ cell tumors.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
14
3
2020
medline:
23
9
2020
entrez:
14
3
2020
Statut:
ppublish
Résumé
Although testicular cancer remains a highly curable malignancy, challenges and uncertainty still remain in certain aspects of management. Residual disease after chemotherapy in patients with germ cell tumors (GCT) remains one of these challenges. We aim to highlight the recent literature on the management of residual disease after chemotherapy in GCT and the emerging innovations that may provide further guidance into this area. A subset of patients with GCT will have residual disease after chemotherapy, and management of these patients involves highly skilled multidisciplinary experts including medical oncologists, surgeons, radiologists, and pathologists. Management options depend on histologic subtype, either seminoma or nonseminoma, and involve size criteria, possible further imaging modalities, and tumor markers. Even with these tools at highly specialized expert centers, uncertainty in management remains, and recent literature has explored the use of newer biomarkers to aid in these cases. Postchemotherapy residual masses in GCT can prove to be complicated cases to manage. Balancing survival with quality of life outcomes is important and requires a multidisciplinary team experienced in treating GCT.
Identifiants
pubmed: 32168037
doi: 10.1097/CCO.0000000000000619
pii: 00001622-202005000-00012
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
250-255Références
SEER Cancer Stat Facts: Testicular Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/testis.html. Accessed 10 May, 2019.
Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New Engl J Med 1987; 316:1435–1440.
Kollmannsberger C, Tyldesley S, Moore C, et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol 2010; 22:808–814.
Daneshmand S, Albers P, Fosså SD, et al. Contemporary management of postchemotherapy testis cancer. Eur Urol 2012; 62:867–876.
Pierorazio PM, Biles MJ. Indications for surgery in disseminated seminoma. Urol Clin 2019; 46:399–407.
Tandstad T, Kollmannsberger CK, Roth BJ, et al. Practice makes perfect: the rest of the story in testicular cancer as a model curable neoplasm. J Clin Oncol 2017; 35:3525.
Flechon A, Bompas E, Biron P, et al. Management of postchemotherapy residual masses in advanced seminoma. J Urol 2002; 168:1975–1979.
Herr HW, Sheinfeld J, Puc HS, et al. Surgery for a postchemotherapy residual mass in seminoma. J Urol 1997; 157:860–862.
Schultz SM, Einhorn LH, Conces DJ Jr, et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989; 7:1497–1503.
De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22:1034–1039.
Stephens AW, Gonin R, Hutchins GD, et al. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996; 14:1637–1641.
Cathomas R, Klingbiel D, Bernard BD, et al. FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry. Am Soc Clin Oncol 2017; 4521–4521.
Mosharafa AA, Foster RS, Leibovich BC, et al. Is postchemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 2003; 169:2126–2128.
Rice KR, Beck SD, Bihrle R, et al. Survival analysis of pure seminoma at postchemotherapy retroperitoneal lymph node dissection. J Urol 2014; 192:1397–1402.
Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23:6549–6555.
Miller KD, Loehrer PJ, Gonin R, et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 1997; 15:1427–1431.
Adra N, Abonour R, Althouse SK, et al. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience. J Clin Oncol 2017; 35:1096.
Donohue JP, Thornhill JA, Foster RS, et al. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 1995; 153:85–89.
Ghodoussipour S, Daneshmand S. Postchemotherapy resection of residual mass in nonseminomatous germ cell tumor. Urol Clin 2019; 46:389–398.
Mano R, Di Natale R, Sheinfeld J. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer, urologic oncology: seminars and original investigations. Elsevier 2019; 37:209–218.
Shayegan B, Carver BS, Stasi J, et al. Clinical outcome following postchemotherapy retroperitoneal lymph node dissection in men with intermediate-and poor-risk nonseminomatous germ cell tumour. BJU Int 2007; 99:993–997.
International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15:594–603.
Fizazi K, Oldenburg J, Dunant A, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 2007; 19:259–264.
Pfannenberg AC, Oechsle K, Bokemeyer C, et al. The role of [18 F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of postchemotherapy residual masses in metastatic germ cell tumors—prospects for management. World J Urol 2004; 22:132–139.
Ravi P, Gray K, O’Donnell E, et al. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic nonseminomatous germ cell tumor. Ann Oncol 2013; 25:331–338.
Kollmannsberger C, Daneshmand S, So A, et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 2009; 28:537–542.
Ehrlich Y, Brames MJ, Beck S, et al. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission. J Clin Oncol 2010; 28:531–536.
Beck SD, Foster RS, Bihrle R, et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 2005; 23:6149–6156.
Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993; 11:324–329.
Gilligan TD, Seidenfeld J, Basch EM, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 2010; 28:3388–3404.
Murray MJ, Huddart RA, Coleman N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol 2016; 13:715.
Nappi L, Nichols C. MicroRNAs as biomarkers for germ cell tumors. Urol Clin North Am 2019; 46:449–457.
van Agthoven T, Looijenga LH. Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test). Oncotarget 2017; 8:58037.
Syring I, Bartels J, Holdenrieder S, et al. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. J Urol 2015; 193:331–337.
Bezan A, Gerger A, Pichler M. MicroRNAs in testicular cancer: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 2014; 34:2709–2713.
van Agthoven T, Eijkenboom WM, Looijenga LH. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients. Cell Oncol 2017; 40:379–388.
Dieckmann K-P, Radtke A, Geczi L, et al. Serum levels of MicroRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol 2019; 37:1412–1423.
Nappi L, Thi M, Lum A, et al. Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum. J Clin Oncol 2019; 18:02057.